Singapore markets closed
Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
63,880.80 +3,819.80 (+6.36%) CMC Crypto 200
1,359.39 +82.41 (+6.45%)
Ultragenyx Pharmaceutical Inc. (RARE)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 43.20 |
| Open | 44.88 |
| Bid | 42.71 x 200 |
| Ask | 42.85 x 200 |
| Day's range | 42.67 - 45.51 |
| 52-week range | 31.52 - 54.98 |
| Volume | |
| Avg. volume | 717,466 |
| Market cap | 3.554B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GuruFocus.com
Ultragenyx Pharmaceutical Inc (RARE) (Q1 2024) Earnings Call Transcript Highlights: Key ...
Explore Ultragenyx Pharmaceutical's Q1 2024 financial performance, strategic milestones, and expert insights from the latest earnings call.
- Zacks
Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
Ultragenyx (RARE) reports dismal first-quarter 2024 results, missing both earnings and revenue estimates, despite the year-over-year increase of Crysvita and Dojolvi sales.
- GuruFocus.com
Ultragenyx Pharmaceutical Inc (RARE) Q1 2024 Earnings: Misses EPS Estimates, Revenue Grows ...
Comprehensive Analysis of Ultragenyx's Latest Financial Performance and Future Outlook
© 2024 Yahoo. All rights reserved.